The process of discovering new drugs can be expensive and time-consuming. AI platforms are being developed to help speed up this process and offer an alternative to traditional methods.
Adnexus has developed the AI platform Sutra™ to accelerate early drug discovery and build intellectual property. The platform utilizes a comprehensive data repository containing details on 19 viruses, a meticulously curated library of 8 million molecules, and human microbiome samples. One of its significant achievements is the successful production of Universal, Broadly Neutralizing, durable monoclonal antibodies unaffected by virus mutations. This success is a testament to Sutra’s potential to make significant advancements in groundbreaking drug development. The primary objective of Sutra™ is to create robust models and make substantial progress in developing groundbreaking drugs. These drugs will demonstrate effectiveness and have the potential to revolutionize the landscape of treatments for infectious and neurological diseases, thereby significantly impacting the biomedical industry.
Scroll over the Tree of Life to view our progress. Click to read more.
Sutra™ has helped Adnexus move forward expeditiously with the monoclonal antibody discovery and development. Adnexus continues to forge ahead to identify novel biomarkers and therapeutic targets, design innovative diagnostic and prognostic tests, and expand the Company’s Patent portfolio. Adnexus continues to partner with technology, genetics, diagnostic, and regulatory companies with that strategy in each of these areas.
1. An Artificial Intelligence Platform for Genomic Surveillance and Monitoring of virus epidemiology.
2. Application of A.I. to analyze the amino acid sequences of the targeted viruses to identify conserved, immutable, and neutralizable sites on the targeted viruses.
Extensive A.I. analysis of 2.8 million SARS-CoV-2 isolates confirmed the 19 immutable sites to be conserved in ALL Variants of Concern and Variants of Interest. The Company’s Artificial Intelligence platform has been used to build 3D Models of all the 19 conserved targets.
The analysis of the SARS-CoV-2 spike protein revealed that all epitopes identified by the Company are linear on the spike proteins, accessible by antibodies, neutralizable, and unaffected by mutations. An extensive A.I. Analysis of 87,500 HIV isolates confirmed eight immutable sites on the HIV. A.I. confirmed the KLIC amino acid binding site sequences targeted By the Company’s primary anti-HIV monoclonal antibody are 100% conserved.
The KLIC binding site on the HIV has remained unchanged in the past decades, as confirmed by the Company’s analysis of the Los Alamos National Database of HIV sequences. This means that even mutations of the HIV will contain this neutralizable site, and virus escape will not occur in treatment with the Company’s anti-HIV antibody.
Using the proprietary methodology, we have identified conserved immutable sites on the following viruses mentioned below.
VIRUS | AI ANALYSIS COMPLETE |
HIV | 8 Conserved Sequences |
SARS-CoV-2 | 19 Conserved Sequences |
HTLV-1 | Multiple Conserved Sequences* |
INFLUENZA A | Multiple Conserved Sequences |
INFLUENZA B | Multiple Conserved Sequences |
INFLUENZA C | Multiple Conserved Sequences |
KOALA RETROVIRUS | Multiple Conserved Sequences |
VIRUS | AI ANALYSIS COMPLETE |
Monkey Pox | Multiple Conserved Sequences |
HINI Influenza | Multiple Conserved Sequences |
Herpes | Multiple Conserved Sequences* |
Elephant Endotheliotropic Herpes Virus | Multiple Conserved Sequences |
Equine Infectious Anemia | Multiple Conserved Sequences |
Feline Immunodeficiency Virus | Multiple Conserved Sequences |
Feline Leukemia Virus | Multiple Conserved Sequences |
Smallpox | Multiple Conserved Sequences |
3. A comprehensive A.I. protocol for producing Monoclonal Antibodies, including implementing A.I. analysis of existing viruses and any new virus immediately upon its emergence globally.
4. Collaboration with biotechnology companies and veterinary institutions in early drug discovery and development programs, increasing safety, efficacy, and probability of success. A joint paper published with Intel Corporation provides more details regarding this collaboration.
5. Adnexus A.I. Human Microbiome Consortium
A.I. is a significant driver for advancing healthcare, and understanding the Human Microbiome will be pivotal to that transformation to unlock the potential of the Human Microbiome by utilizing Artificial Intelligence.
Adnexus is building on the consortium to utilize A.I. to assess the effects of nutrition, genetics, and the human microbiome on diseases. This is a part of the Company’s long-term strategy to enter the personalized medicine market and build a robust Intellectual Property portfolio covering its discoveries.
This focus includes:
- Building prediction models for infectious diseases, Alzheimer’s, and chronic medical diseases.
- Identifying biomarkers for infectious diseases, Alzheimer’s disease, and chronic medical diseases.
- Identifying novel targets and clear intervention strategies for infectious diseases. Alzheimer’s disease and chronic medical diseases
6. A.I. driven diagnostics
Adnexus employs Artificial Intelligence in in-vitro diagnostic tests that diagnose viral diseases based on the presence of the conserved sites that remain unaffected by mutations. Adnexus has identified conserved targets for numerous infectious diseases for humans and animals. The Company has identified conserved targets for SARS-CoV-2, HIV, rabies, influenza A, influenza B, HTLV1, Herpes, Smallpox, Ebola, Equine Infectious Anemia, Feline leukemia virus, Feline immunodeficiency virus, Respiratory Syncytial Virus, and Koala Retrovirus.
Documented studies show better clinical outcomes and delayed progression of diseases if patients have the antibodies to the conserved targets. Adnexus works on prognostic tests utilizing A.I. to predict the immune response before receiving viral therapy. This will allow physicians to understand if a patient will respond favorably to a particular antiviral treatment.
For more information on our services and research projects, please click here to submit an enquiry.
